

Sirolimus - Wet AMD Subconjunctival and intravitreal

Sirolimus (MacuSight inc.), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation.

It was originally developed as an antifungal agent and has potent immunosuppressive and antiproliferative properties.

Sirolimus inhibits the mammalian target of rapamycin (mTOR).

The mammalian target of rapamycin is a protein kinase that regulates cell growth and metabolism in response to changes in the environment.

Sirolimus administered via subconjunctival injections was as effective as sirolimus administered via intravitreal injection.

A phase II, randomized, multicentric study in wet AMD is now taking place; (EMERALD) is currently recruiting patients with wet AMD for a phase II study of an ocular sirolimus formulation in combination with Lucentis®.

This is a randomized, multicentric study and is taking place throughout the United States [\(29\)](#).

[View PDF](#)